Letter | Published:

3K3A–activated protein C stimulates postischemic neuronal repair by human neural stem cells in mice

Nature Medicine volume 22, pages 10501055 (2016) | Download Citation

Abstract

Activated protein C (APC) is a blood protease with anticoagulant activity and cell-signaling activities mediated by the activation of protease-activated receptor 1 (F2R, also known as PAR1) and F2RL1 (also known as PAR3) via noncanonical cleavage1. Recombinant variants of APC, such as the 3K3A-APC (Lys191–193Ala) mutant in which three Lys residues (KKK191–193) were replaced with alanine, and/or its other mutants with reduced (>90%) anticoagulant activity, engineered to reduce APC-associated bleeding risk while retaining normal cell-signaling activity, have shown benefits in preclinical models of ischemic stroke2,3,4,5,6, brain trauma7, multiple sclerosis8, amyotrophic lateral sclerosis9, sepsis10,11, ischemic and reperfusion injury of heart12, kidney and liver13, pulmonary, kidney and gastrointestinal inflammation1,11, diabetes14 and lethal body radiation15. On the basis of proof-of-concept studies and an excellent safety profile in humans, 3K3A-APC has advanced to clinical trials as a neuroprotectant in ischemic stroke16,17. Recently, 3K3A-APC has been shown to stimulate neuronal production by human neural stem and progenitor cells (NSCs) in vitro18 via a PAR1–PAR3–sphingosine-1-phosphate-receptor 1–Akt pathway19, which suggests the potential for APC-based treatment as a strategy for structural repair in the human central nervous (CNS) system. Here we report that late postischemic treatment of mice with 3K3A-APC stimulates neuronal production by transplanted human NSCs, promotes circuit restoration and improves functional recovery. Thus, 3K3A-APC-potentiated neuronal recruitment from engrafted NSCs might offer a new approach to the treatment of stroke and related neurological disorders.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , & Activated protein C: biased for translation. Blood 125, 2898–2907 (2015).

  2. 2.

    et al. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat. Med. 9, 338–342 (2003).

  3. 3.

    et al. Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage. Nat. Med. 12, 1278–1285 (2006).

  4. 4.

    , , , & Activated protein C promotes neovascularization and neurogenesis in postischemic brain via protease-activated receptor 1. J. Neurosci. 28, 12788–12797 (2008).

  5. 5.

    et al. An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents. Stroke 43, 2444–2449 (2012).

  6. 6.

    et al. Activated protein C analog protects from ischemic stroke and extends the therapeutic window of tissue-type plasminogen activator in aged female mice and hypertensive rats. Stroke 44, 3529–3536 (2013).

  7. 7.

    et al. Activated protein C analog with reduced anticoagulant activity improves functional recovery and reduces bleeding risk following controlled cortical impact. Brain Res. 1347, 125–131 (2010).

  8. 8.

    et al. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 451, 1076–1081 (2008).

  9. 9.

    et al. Blood-spinal cord barrier disruption contributes to early motor-neuron degeneration in ALS-model mice. Proc. Natl. Acad. Sci. USA 111, E1035–E1042 (2014).

  10. 10.

    et al. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J. Clin. Invest. 79, 918–925 (1987).

  11. 11.

    Protein C anticoagulant system—anti-inflammatory effects. Semin. Immunopathol. 34, 127–132 (2012).

  12. 12.

    et al. Activated protein C protects against myocardial ischemia/reperfusion injury via inhibition of apoptosis and inflammation. Arterioscler. Thromb. Vasc. Biol. 29, 1087–1092 (2009).

  13. 13.

    , , , & Human activated protein C attenuates both hepatic and renal injury caused by hepatic ischemia and reperfusion injury in mice. Kidney Int. 76, 739–750 (2009).

  14. 14.

    et al. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat. Med. 13, 1349–1358 (2007).

  15. 15.

    et al. Pharmacological targeting of the thrombomodulin-activated protein C pathway mitigates radiation toxicity. Nat. Med. 18, 1123–1129 (2012).

  16. 16.

    et al. Phase 1 safety, tolerability and pharmacokinetics of 3K3A-APC in healthy adult volunteers. Curr. Pharm. Des. 19, 7479–7485 (2013).

  17. 17.

    Safety evaluation of 3K3A-APC in ischemic stroke (RHAPSODY); 2014 August 18; .

  18. 18.

    et al. Prospective identification, isolation, and profiling of a telomerase-expressing subpopulation of human neural stem cells, using sox2 enhancer-directed fluorescence-activated cell sorting. J. Neurosci. 30, 14635–14648 (2010).

  19. 19.

    et al. An activated protein C analog stimulates neuronal production by human neural progenitor cells via a PAR1-PAR3-S1PR1-Akt pathway. J. Neurosci. 33, 6181–6190 (2013).

  20. 20.

    Cell therapies: careful translation from animals to patients. Stroke 44 (Suppl. 1), S107–S109 (2013).

  21. 21.

    et al. High-yield selection and extraction of two promoter-defined phenotypes of neural stem cells from the fetal human brain. Nat. Biotechnol. 19, 843–850 (2001).

  22. 22.

    et al. Stroke Treatment Academic Industry Roundtable (STAIR) recommendations for maximizing the use of intravenous thrombolytics and expanding treatment options with intra-arterial and neuroprotective therapies. Stroke 42, 2645–2650 (2011).

  23. 23.

    et al. Transplanted human fetal neural stem cells survive, migrate, and differentiate in ischemic rat cerebral cortex. Proc. Natl. Acad. Sci. USA 101, 11839–11844 (2004).

  24. 24.

    et al. Administration of CD34+ cells after stroke enhances neurogenesis via angiogenesis in a mouse model. J. Clin. Invest. 114, 330–338 (2004).

  25. 25.

    et al. Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat. Med. 12, 441–445 (2006).

  26. 26.

    & Recombinant human erythropoietin increases cerebral cortical width index and neurogenesis following ischemic stroke. Neural Regen. Res. 7, 578–582 (2012).

  27. 27.

    et al. Activated protein C analog promotes neurogenesis and improves neurological outcome after focal ischemic stroke in mice via protease activated receptor 1. Brain Res. 1507, 97–104 (2013).

  28. 28.

    et al. Neurons derived from transplanted neural stem cells restore disrupted neuronal circuitry in a mouse model of spinal cord injury. J. Clin. Invest. 120, 3255–3266 (2010).

  29. 29.

    et al. Imaging neural activity in worms, flies and mice with improved GCaMP calcium indicators. Nat. Methods 6, 875–881 (2009).

  30. 30.

    & Mesoscale transcranial spontaneous activity mapping in GCaMP3 transgenic mice reveals extensive reciprocal connections between areas of somatomotor cortex. J. Neurosci. 34, 15931–15946 (2014).

  31. 31.

    et al. A Cre-dependent GCaMP3 reporter mouse for neuronal imaging in vivo. J. Neurosci. 32, 3131–3141 (2012).

  32. 32.

    , , , & New tools for investigating astrocyte-to-neuron communication. Front. Cell. Neurosci. 7, 193 (2013).

  33. 33.

    et al. Transplanted stem cell-secreted vascular endothelial growth factor effects poststroke recovery, inflammation, and vascular repair. Stem Cells 29, 274–285 (2011).

  34. 34.

    et al. Cell fusion-independent differentiation of neural stem cells to the endothelial lineage. Nature 430, 350–356 (2004).

  35. 35.

    Stem and progenitor cell-based therapy of the central nervous system: hopes, hype, and wishful thinking. Cell Stem Cell 18, 174–188 (2016).

  36. 36.

    Transplantation tolerance: from theory to clinic. Immunol. Rev. 258, 64–79 (2014).

  37. 37.

    et al. Recovery of sensorimotor function after distal middle cerebral artery photothrombotic occlusion in rats. Stroke 25, 153–159 (1994).

  38. 38.

    et al. Preclinical safety and pharmacokinetic profile of 3K3A-APC, a novel, modified activated Protein C for ischemic stroke. Curr. Pharm. Des. 18, 4215–4222 (2012).

  39. 39.

    et al. The adhesive removal test: a sensitive method to assess sensorimotor deficits in mice. Nat. Protoc. 4, 1560–1564 (2009).

  40. 40.

    et al. Behavioral deficits after distal focal cerebral ischemia in mice: Usefulness of adhesive removal test. Behav. Neurosci. 123, 224–230 (2009).

  41. 41.

    , , & A diphtheria toxin receptor deficient in epidermal growth factor-like biological activity. J. Biochem. 140, 831–841 (2006).

  42. 42.

    et al. Diphtheria toxin receptor-mediated conditional and targeted cell ablation in transgenic mice. Nat. Biotechnol. 19, 746–750 (2001).

  43. 43.

    , , & Control of synapse number by glia. Science 291, 657–661 (2001).

Download references

Acknowledgements

The authors want to acknowledge the NIH grants 9R01NS090904-16 (B.V.Z.), RO1HL052246 and PO1 HL031950 (J.H.G.), R01NS75345 (S.A.G.); National Natural Science Foundation of China grant 31371116 (Y.Z.); and grants from the Adelson Medical Research Foundation, New York State Stem Cell Research Board (NYSTEM), Novo Nordisk Foundation, Lundbeck Foundation, National Multiple Sclerosis Society and ALS Association (S.A.G.).

Author information

Author notes

    • Yaoming Wang
    •  & Zhen Zhao

    These authors contributed equally to this work.

Affiliations

  1. Department of Physiology and Biophysics, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA.

    • Yaoming Wang
    • , Zhen Zhao
    • , Sanket V Rege
    • , Min Wang
    • , Gabriel Si
    •  & Berislav V Zlokovic
  2. The Zilkha Neurogenetic Institute, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA.

    • Yaoming Wang
    • , Zhen Zhao
    • , Sanket V Rege
    • , Min Wang
    • , Gabriel Si
    •  & Berislav V Zlokovic
  3. Department of Neurobiology, Chongqing Key Laboratory of Neurobiology, Third Military Medical University, Shapingba District, Chongqing, China.

    • Yi Zhou
  4. Center for Translational Neuromedicine, University of Rochester Medical Center, Rochester, New York, USA.

    • Su Wang
    •  & Steven A Goldman
  5. Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA.

    • Su Wang
    •  & Steven A Goldman
  6. Center for Basic and Translational Neuroscience, University of Copenhagen Faculty of Health and Medical Sciences, Copenhagen, Denmark.

    • Su Wang
    •  & Steven A Goldman
  7. Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA.

    • John H Griffin
  8. Division of Hematology/Oncology, Department of Medicine, University of California, San Diego, San Diego, California, USA.

    • John H Griffin

Authors

  1. Search for Yaoming Wang in:

  2. Search for Zhen Zhao in:

  3. Search for Sanket V Rege in:

  4. Search for Min Wang in:

  5. Search for Gabriel Si in:

  6. Search for Yi Zhou in:

  7. Search for Su Wang in:

  8. Search for John H Griffin in:

  9. Search for Steven A Goldman in:

  10. Search for Berislav V Zlokovic in:

Contributions

Y.W. and Z.Z. designed and performed experiments and analyzed data; Z.Z. contributed to writing the manuscript; S.V.R., M.W. and G.S. performed experiments; Y.Z. customized the Matlab program; J.H.G. and S.A.G. edited the manuscript; S.W. and S.A.G. contributed crucial materials and comments on the text; B.V.Z. designed all experiments, analyzed data and wrote the manuscript.

Competing interests

B.V.Z. is a founder of ZZ Biotech LLC, a biotechnology company with a mission to develop APC and its functional mutants for the treatment of stroke and other neurological disorders. J.H.G. is a consultant for ZZ Biotech LLC and an inventor for some uses of 3K3A-APC.

Corresponding author

Correspondence to Berislav V Zlokovic.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Figures 1–9

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nm.4154

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing